← Back to Search

Angiotensin II Receptor Blocker/Thiazide Diuretic Combination

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

Phase 4
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4, 8, 12, 16, end of study (for patients that did not complete the last visit at week 16)
Awards & highlights
Approved for 20 Other Conditions
Drug Has Already Been Approved
Pivotal Trial
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure \[MSSBP\] \>150 mmHg) patients.

Eligible Conditions
  • High Blood Pressure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4, 8, 12, 16, end of study (for patients that did not complete the last visit at week 16)
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4, 8, 12, 16, end of study (for patients that did not complete the last visit at week 16) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change From Baseline in Postprandial Glucose
Insulin
Change From Baseline in Postprandial Non-esterified Fatty Acids
+2 more

Awards & Highlights

Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: valsartan/HCTZExperimental Treatment1 Intervention
Group II: HCTZ +AmlodipineActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hydrochlorothiazide
FDA approved

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,921 Previous Clinical Trials
4,253,900 Total Patients Enrolled
~22 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top